Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

BIOLOGICAL2 trials

Conditions

Allogeneic Stem Cell Transplant RecipientBlasts 10 Percent or More of Bone Marrow Nucleated CellsRecurrent Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Phase 1

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT01787474

M.D. Anderson Cancer CenterRecurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Start: 2014-05-19End: 2021-06-17Updated: 2021-06-21

Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML

CompletedNCT04220684

Sumithira VasuAllogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia +1

Start: 2020-06-11End: 2024-10-22Updated: 2026-01-09

Blood2023-11-021 citations

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Universally Alloreactive Donor-Derived Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood2021-11-055 citations

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood2020-11-042 citations

A phase I clinical trial testing the safety of IL-21-expanded, off-the-shelf, natural killer cells for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.

Journal of Clinical Oncology2020-05-206 citations

Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.

Journal of Clinical Oncology2018-05-206 citations

Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

Sponsors

Conditions

Phase 1

Related Papers